Despite new developments in innovative and potentially targeted drugs like hypomethylating
agents (HMA), allogeneic hematopoietic stem cell transplantation (HCT) is still the only …

Allogeneic hematopoietic stem cell transplantation (allo-HCT) can cure a proportion of
patients with myelodysplastic syndromes (MDS). However, MDS remains a disease of the …

Allogeneic hematopoietic stem cell transplantation (SCT) can cure a proportion of patients
with myelodysplastic syndromes (MDS). However, treatment related toxicities, graft versus …

The sole curative therapy for myelodysplastic syndrome (MDS) is allogeneic hematopoietic
cell transplantation (HCT). Here this therapeutic modality is reviewed and critically evaluated …

Recently, a refined cytogenetic and molecular classification fundamentally changed the
prognostication of patients with myelodysplastic syndromes (MDS). The increasingly …

Allogeneic stem cell transplantation (SCT) is the only therapeutic modality at present that
may be delivered with curative intent in patients with myelodysplastic syndromes (MDS) …

Allogeneic haematopoietic stem cell transplantation is curative in up to 40% of
myelodysplastic syndrome patients. Appropriate patient selection, modification of …

Hematopoietic cell transplantation (HCT) offers potentially curative therapy for patients with
myelodysplastic syndromes (MDS). However, who should and can be transplanted, with …

Allogeneic hematopoietic stem cell transplantation (HCT) offers potentially curative therapy
for patients with myelodysplastic syndromes (MDS). However, who should and can be …

Myelodysplastic syndromes (MDS) mainly affect the elderly population, which implies that
the majority of patients cannot tolerate intensive therapeutic approaches, including …